Human papillomavirus infections as a marker to predict overall survival in lung adenocarcinoma

International Journal of Cancer

Volumn 134, Issue 1, 2014, Pages 65-71

  Wang, Jinn Li ^a,b   Fang, Chia Lang ^a,c   Wang, Mey ^b,d   Yu, Ming Chih ^a   Bai, Kuan Jen ^a   Lu, Pei Chih ^a   Liu, H Eugene ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d Center for Drug Evaluation   (Taiwan)

Author keywords

human papillomavirus; lung adenocarcinoma; survival

Indexed keywords

CAPSID PROTEIN L1; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN E6;

AGE; AGED; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUTATION RATE; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; SMOKING; SURVIVAL PREDICTION; TAIWAN; TUMOR VOLUME;

HUMAN PAPILLOMAVIRUS; LUNG ADENOCARCINOMA; SURVIVAL;

ADENOCARCINOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84885960644     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28349     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Taiwan RoCDoHCrarIC. Taiwan, Republic of China: Department of Health. [Cancer registry annual report]. (In Chinese), 2010.
3. Scagliotti GV, Longo M, Novello S,. Nonsmall cell lung cancer in never smokers. Curr Opin Oncol 2009; 21: 99-104.
4. Ko YC, Lee CH, Chen MJ, et al. Risk factors for primary lung cancer among non-smoking women in Taiwan. Int J Epidemiol 1997; 26: 24-31.
5. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005; 97: 339-46.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
7. Petrelli F, Borgonovo K, Cabiddu M, et al. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials. Clin Lung Cancer 2012; 13: 107-14.
8. Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-65.
9. Werness BA, Levine AJ, Howley PM,. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248: 76-9.
10. Dyson N, Howley PM, Munger K, et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-7.
11. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-31.
12. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003; 104: 336-44.
13. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
14. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-9.
15. Cheng YW, Chiou HL, Sheu GT, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res 2001; 61: 2799-803.
16. Kato T, Koriyama C, Khan N, et al. EGFR mutations and human papillomavirus in lung cancer. Lung Cancer 2012; 78: 144-7.
17. Baba M, Castillo A, Koriyama C, et al. Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas. Oncol Rep 2010; 23: 1085-92.
18. Lee CN, Yu MC, Bai KJ, et al. NAT2 fast acetylator genotypes are associated with an increased risk for lung cancer with wildtype epidermal growth factor receptors in Taiwan. Lung Cancer 2009; 64: 9-12.
19. Mantovani F, Banks L,. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 2001; 20: 7874-87.
20. Li T, Lu ZM, Chen KN, et al. Human papillomavirus type 16 is an important infectious factor in the high incidence of esophageal cancer in Anyang area of China. Carcinogenesis 2001; 22: 929-34.
21. Chen XS, Garcea RL, Goldberg I, et al. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000; 5: 557-67.
22. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-8.
23. Posner MR, Lorch JH, Goloubeva O, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: a subset analysis from an international phase III trial. Ann Oncol 2011; 22: 1071-7.
24. Goldenberg D, Begum S, Westra WH, et al. Cystic lymph node metastasis in patients with head and neck cancer: an HPV-associated phenomenon. Head Neck 2008; 30: 898-903.
25. Lassen P,. The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010; 95: 371-80.
26. Hsu NY, Cheng YW, Chan IP, et al. Association between expression of human papillomavirus 16/18 E6 oncoprotein and survival in patients with stage I non-small cell lung cancer. Oncol Rep 2009; 21: 81-7.
27. Petrelli F, Sarti E, Barni S,. Predictive value of HPV in oropharyngeal carcinoma treated with radiotherapy: an updated systematic review and meta-analysis of 30 trials. Head Neck 2013 Apr 22. doi:10.1002/hed.23351.
28. Park CM, Park MJ, Kwak HJ, et al. Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin. Int J Oncol 2006; 28: 119-25.
29. Basu A, Krishnamurthy S,. Cellular responses to cisplatin-induced DNA damage. J Nucleic Acids 2010; 2010: 1-16, doi:10.4061/2010/201367.
30. Crook T, Wrede D, Vousden KH,. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 1991; 6: 873-5.
31. Butz K, Geisen C, Ullmann A, et al. Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. Int J Cancer 1996; 68: 506-13.
32. Blagosklonny MV,. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J 2000; 14: 1901-7.
33. Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996; 56: 556-62.
34. Reles A, Wen WH, Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7: 2984-97.
35. Toyooka S, Takano T, Kosaka T, et al. Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. Cancer Sci 2008; 99: 303-8.
36. Castellsague X, Schneider A, Kaufmann AM, et al. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 2009; 115: S15-S23.